MARKET

CDNA

CDNA

CareDx
NASDAQ

Real-time Quotes | Nasdaq Last Sale

21.85
-1.53
-6.54%
After Hours: 21.85 0 0.00% 16:56 03/27 EDT
OPEN
22.20
PREV CLOSE
23.38
HIGH
23.30
LOW
21.79
VOLUME
643.57K
TURNOVER
--
52 WEEK HIGH
41.27
52 WEEK LOW
13.04
MARKET CAP
936.92M
P/E (TTM)
-41.8182
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of CDNA and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average CDNA stock price target is 45.00 with a high estimate of 59.00 and a low estimate of 35.00.

EPS

CDNA News

More
  • Edited Transcript of CDNA earnings conference call or presentation 27-Feb-20 9:30pm GMT
  • Thomson Reuters StreetEvents · 3d ago
  • REPEAT - New AJT Publication: AlloSure Monitors First Patient Retransplanted After Anti-PD-L1 Cancer Therapy
  • GlobeNewswire · 03/20 12:00
  • The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates
  • Benzinga · 03/18 11:36
  • Are Options Traders Betting on a Big Move in CareDx (CDNA) Stock?
  • Zacks · 03/17 15:10

Industry

Biotechnology & Medical Research
-2.43%
Pharmaceuticals & Medical Research
-0.87%

Hot Stocks

Symbol
Price
%Change

About CDNA

CareDx, Inc. is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company's commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection. Its products under development for transplant monitoring include AlloSure, a development-stage transplant surveillance solution, which applies next generation sequencing to detect and quantitate genetic differences between donor-derived cell-free deoxyribonucleic acid (dd-cfDNA) in the blood stream emanating from the donor heart. It offers the AlloMap Score Variability service, which provides complementary information to help personalize long-term care of heart transplant recipients.
More

Webull offers kinds of CareDx Inc stock information, including NASDAQ:CDNA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CDNA stock news, and many more online research tools to help you make informed decisions.